New development in the mechanistic understanding of peptic ulcer diseases

Drug Discovery Today: Disease Mechanisms

Volumn 3, Issue 4, 2006, Pages 431-437

  Lu, Hong ^a   Graham, David Y ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMOXICILLIN; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ARTHROTEC; ASCORBIC ACID; CELECOXIB; CHOLERA TOXIN; CLARITHROMYCIN; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DNA VACCINE; HELICOBACTER PYLORI VACCINE; LACTOFERRIN; LANSOPRAZOLE; METRONIDAZOLE; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROBIOTIC AGENT; PRONASE; PROTON PUMP INHIBITOR; RANITIDINE; ROFECOXIB; STOMACH SECRETION INHIBITOR; TETRACYCLINE; TINIDAZOLE; TYPHOID VACCINE; UNINDEXED DRUG; VALDECOXIB;

ADJUVANT THERAPY; ANTIBIOTIC RESISTANCE; BACTERIAL IMMUNITY; BACTERIAL VIRULENCE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG USE; DUODENUM ULCER; ERADICATION THERAPY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IMMUNIZATION; INNATE IMMUNITY; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; PATHOGENESIS; PEPTIC ULCER; PRIMARY PREVENTION; REVIEW; STOMACH ACID SECRETION; STOMACH ULCER; TASTE DISORDER; TREATMENT DURATION; ULCER HEALING;

EID: 33847111729     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2006.07.001     Document Type: Review

References (37)

1. Shiotani A., et al. Pathogenesis and therapy of gastric and duodenal ulcer disease. Med. Clin. N. Am. 86 (2002) 1447-1466 (viii)
2. Nakayama Y., et al. Helicobacter pylori infection: diagnosis and treatment. Expert Rev. Anti-infect. Ther. 2 (2004) 599-610
3. De Francesco V., et al. The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomized study. Dig. Liver Dis. 36 (2004) 322-326
4. Zullo A., et al. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment. Pharmacol. Ther. 17 (2003) 719-726
5. de Boer W.A., et al. Sequential therapy; a new treatment for Helicobacter pylori infection. But is it ready for general use?. Dig. Liver Dis. 36 (2004) 311-314
6. Guttner Y., et al. Human recombinant lactoferrin is ineffective in the treatment of human Helicobacter pylori infection. Aliment. Pharmacol. Ther. 17 (2003) 125-129
7. Opekun A.R., et al. Novel therapies for Helicobacter pylori infection. Aliment. Pharmacol. Ther. 13 (1999) 35-42
8. Di Mario F., et al. Use of bovine lactoferrin for Helicobacter pylori eradication. Dig. Liver Dis. 35 (2003) 706-710
9. Zullo A., et al. Quadruple therapy with lactoferrin for Helicobacter pylori eradication: a randomised, multicentre study. Dig. Liver Dis. 37 (2005) 496-500
10. Casswall T.H., et al. Bovine anti-Helicobacter pylori antibodies for oral immunotherapy. Scand. J. Gastroenterol. 37 (2002) 380-385
11. Suzuki H., et al. Effect of dietary anti-Helicobacter pylori-urease immunoglobulin Y on Helicobacter pylori infection. Aliment. Pharmacol. Ther. 20 Suppl. (2004) 185-192
12. Huynh H.Q., et al. N-acetylcysteine, a novel treatment for Helicobacter pylori infection. Dig. Dis. Sci. 49 (2004) 853-1861
13. Gurbuz A.K., et al. Effect of N-acetyl cysteine on Helicobacter pylori. South. Med. J. 98 (2005) 1095-1097
14. Gotoh A., et al. Additive effect of pronase on the efficacy of eradication therapy against Helicobacter pylori. Helicobacter 7 (2002) 183-191
15. Jarosz M., et al. Effects of high dose vitamin C treatment on Helicobacter pylori infection and total vitamin C concentration in gastric juice. Eur. J. Cancer Prev. 7 (1998) 449-454
16. Chuang C.H., et al. Vitamin C and E supplements to lansoprazole-amoxicillin-metronidazole triple therapy may reduce the eradication rate of metronidazole-susceptible Helicobacter pylori infection. Helicobacter 7 (2002) 310-316
17. Hamilton-Miller J.M. The role of probiotics in the treatment and prevention of Helicobacter pylori infection. Int. J. Antimicrob. Agents 22 (2003) 360-366
18. Michetti P., et al. Effect of whey-based culture supernatant of Lactobacillus acidophilus (johnsonii) La1 on Helicobacter pylori infection in humans. Digestion 60 (1999) 203-209
19. Armuzzi A., et al. The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy. Aliment. Pharmacol. Ther. 15 (2001) 163-169
20. Cremonini F., et al. Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo- controlled study. Am. J. Gastroenterol. 97 (2002) 2744-2749
21. Permin H., et al. Inflammation, immunity, and vaccines for Helicobacter infection. Helicobacter 10 Suppl. 1 (2005) 21-25
22. Aebischer T., et al. Helicobacter pylori vaccine development: facing the challenge. Int. J. Med. Microbiol. 295 (2005) 343-353
23. Michetti P., et al. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology 116 (1999) 804-812
24. Graham D.Y., et al. Challenge model for Helicobacter pylori infection in human volunteers. Gut 53 (2004) 1235-1243
25. Huang J.Q., et al. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 359 (2002) 14-22
26. Bombardier C., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med. 343 (2000) 1520-1528
27. Ashworth N.L., et al. A population based historical cohort study of the mortality associated with nabumetone, Arthrotec, diclofenac, and naproxen. J. Rheumatol. 31 (2004) 951-956
28. Graham D.Y. NSAIDs, Helicobacter pylori, and Pandora's Box. N. Engl. J. Med. 347 (2002) 2162-2164
29. Graham D.Y. Critical effect of Helicobacter pylori infection on the effectiveness of omeprazole for prevention of gastric or duodenal ulcers among chronic NSAID users. Helicobacter 7 (2002) 1-8
30. Silverstein F.E., et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti- inflammatory drugs. A randomized, double-blind, placebo- controlled trial. Ann. Inter. Med. 123 (1995) 241-249
31. Graham D.Y., et al., NSAID-Associated Gastric Ulcer Prevention Study Group. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Archives of Internal Medicine 162 (2002) 169-175
32. Ashworth N.L., et al. A population based historical cohort study of the mortality associated with nabumetone, Arthrotec, diclofenac, and naproxen. J. Rheumatol. 31 (2004) 951-956
33. Ashworth N.L., et al. Risk of hospitalization with peptic ulcer disease or gastrointestinal hemorrhage associated with nabumetone, Arthrotec, diclofenac, and naproxen in a population based cohort study. J. Rheumatol. 32 (2005) 2212-2217
34. Wallace J.L. Recent advances in gastric ulcer therapeutics. Curr. Opin. Pharmacol. 5 (2005) 573-577
35. Lohmander L.S., et al. A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis. Ann. Rheum. Dis. 64 (2005) 449-456
36. Fiorucci S., et al. Co-administration of nitric oxide-aspirin (NCX-4016) and aspirin prevents platelet and monocyte activation and protects against gastric damage induced by aspirin in humans. J. Am. Coll. Cardiol. 44 (2004) 635-641
37. Lichtenberger L.M., et al. Phosphatidylcholine association increases the anti-inflammatory and analgesic activity of ibuprofen in acute and chronic rodent models of joint inflammation: relationship to alterations in bioavailability and cyclooxygenase-inhibitory potency. J. Pharmacol. Exp. Ther. 298 (2001) 279-287